Highlights
- Rhythm Biosciences has appointed Adam Zembrzuski as Chief Commercial Officer, effective 18 November 2026, bringing 21 years of clinical diagnostics and health technology commercialisation experience.
- Mr Zembrzuski's background includes senior roles at Abbott Laboratories and most recently as General Manager at Labflow, where he drove strategic expansion across Australia and Asia-Pacific.
- As CCO, he will lead commercial strategy across ColoSTAT and geneType, including sales, marketing, pricing, reimbursement, and distribution and laboratory partner management.
- The appointment follows Rhythm's establishment of commercial operations for both diagnostic platforms and comes as the company focuses on accelerating Revenue growth and broader market penetration.
Rhythm Biosciences Limited (ASX:RHY) has announced the appointment of Adam Zembrzuski as Chief Commercial Officer, effective 18 November 2026. Mr Zembrzuski brings 21 years of experience across clinical diagnostics, medical devices, and health technology software-as-a-service to a role focused on accelerating revenue growth for the company's commercially available diagnostic platforms.
Rhythm's Diagnostic Portfolio and the Commercial Mandate
Rhythm Biosciences operates two commercially available diagnostic platforms. ColoSTAT is a blood-based test for the detection of colorectal cancer, measuring five specific protein biomarkers to assess the likelihood of disease in symptomatic individuals. It is based on CSIRO research and is intended for use in clinical evaluation of patients with symptoms associated with colorectal cancer. The geneType platform is a broader genetic risk assessment system that combines clinical, family history, and genetic data — including polygenic risk scores — to generate personalised risk assessments across multiple conditions including breast cancer, cardiovascular disease, diabetes, colorectal cancer, prostate cancer, and melanoma.
With commercial operations established for both platforms, the company's near-term priority has shifted from product development to market penetration and revenue growth. The CCO appointment directly addresses this priority, bringing specific expertise in launching diagnostic tests, managing laboratory and distribution partnerships, and engaging with reimbursement authorities.
Mr Zembrzuski's Background and Immediate Priorities
Mr Zembrzuski's most recent role was as General Manager at Labflow, an Australian health technology company, where he led strategic expansion across Australia and the Asia-Pacific region, closed core enterprise and government partnerships, and contributed to shaping the company's commercial positioning through to a successful acquisition. Prior experience includes Country Manager roles at Abbott Laboratories and LivaNova, two globally significant medical technology companies with strong positions in clinical diagnostics and therapeutic devices respectively.
In his initial comments, Mr Zembrzuski identified engagement with key clinical and industry Stakeholders as an immediate priority, with the goal of unlocking the commercial pipeline for ColoSTAT and geneType. The CCO will be accountable for commercial strategy refinement, sales execution in target markets, reimbursement strategy including engagement with Australia's Medical Services Advisory Committee for public funding recommendations, and further development of the company's distribution and laboratory partner network.
Key Insights
The appointment of an experienced commercial leader with a track record in clinical diagnostics is a meaningful step in Rhythm's transition from a development-stage company to a commercially focused diagnostics business. The principal near-term milestones are the development of a strengthened commercial strategy for ColoSTAT in the symptomatic population and geneType in the preventative health market, progress on reimbursement discussions, and the first evidence of revenue growth acceleration attributable to the new commercial organisation.
_11_17_2026_06_50_14_402066.jpg)





Please wait processing your request...